Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma.

Ning, Yang-Min; Maher, V Ellen; Beaver, Julia A; Goldberg, Kirsten B; Blumenthal, Gideon M; Pazdur, Richard

Ning, Yang-Min; Maher, V Ellen; Beaver, Julia A; Goldberg, Kirsten B; Blumenthal, Gideon M; Pazdur, Richard.

Afiliação

Ning YM; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA ningy@cder.fda.gov.
Maher VE; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Beaver JA; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Goldberg KB; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Blumenthal GM; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Pazdur R; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Oncologist ; 23(2): 139-142, 2018 02.

Article em En | MEDLINE | ID: mdl-29180460

Assuntos

Acessibilidade aos Serviços de Saúde; Imunoterapia; Neoplasias Urológicas/terapia; Humanos; Prognóstico; Neoplasias Urológicas/imunologia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Urológicas / Acessibilidade aos Serviços de Saúde / Imunoterapia Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google